Autologous graft-versus-host disease: Harnessing anti-tumor immunity through impaired self-tolerance

Bone Marrow Transplantation

Volumn 41, Issue 6, 2008, Pages 505-513

  Kline, J ^a   Subbiah, S ^b   Lazarus, H M ^b   van Besien, K ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA1 INTERFERON; BUSULFAN; CALCINEURIN INHIBITOR; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; GAMMA INTERFERON; GAMMA1B INTERFERON; MELPHALAN; ROQUINIMEX; STEROID; TACROLIMUS; THIOTEPA;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS GRAFT VERSUS HOST REACTION; BREAST CANCER; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION; KIDNEY FAILURE; LIVER TOXICITY; LYMPHOCYTE DEPLETION; LYMPHOMA; MYELOABLATIVE CONDITIONING; MYELOMA; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RASH; REGULATORY T LYMPHOCYTE; REVIEW; SEPSIS; SKIN BIOPSY; SKIN MANIFESTATION; TUMOR IMMUNITY;

ANIMALS; ANTIVIRAL AGENTS; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; CYCLOSPORINE; DRUG THERAPY, COMBINATION; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; MICE; MODELS, ANIMAL; SELF TOLERANCE; TRANSPLANTATION, AUTOLOGOUS;

EID: 41549085207     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705931     Document Type: Review

References (53)

1. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300 1068-1073.
2. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981, 304: 1529-1533.
3. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: Proof of principle. Blood 1996; 87 1196-1198.
4. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
5. Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801-813.
6. Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19: 406-413.
7. Philip T, Guglielmi C, Hagenbeek Al Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
8. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 2002; 359: 2065-2071.
9. Hood AF, Vogelsang GB, Black LP, Farmer ER, Santos GW. Acute graft-vs-host disease. Development following autologous and syngeneic bone marrow transplantation. Arch Dermatol 1987; 123: 745-750.
10. Jones RJ, Vogelsang GB, Hess AD, Farmer ER, Mann RB, Geller RB et al Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1989; 1: 754-757.
11. Holmberg L, Kikuchi K, Gooley TA, Adams KM, Hockenbery DM, Flowers ME et al. Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: Incidence, risk factors, and outcome. Biol Blood Marrow Transplant 2006; 12: 226-234.
12. Saunders MD, Shulman HM, Murakami CS, Chauncey TR, Bensinger WL, McDonald GB. Bile duct apoptosis and cholestasis resembling acute graft-versus-host disease after autologous hematopoietic cell transplantation. Am J Surg Pathol 2000; 24: 1004-1008.
13. +-purified autologous peripheral blood progenitor cell transplantation. J Hematother Stem Cell Res 2000; 9: 375-379.
14. Baron F, Gothot A, Salmon JP, Hermanne JP, Pierard GE, Fillet G et al Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation. Br J Haematol 2000; 111: 745-753.
15. Glazier A, Tutschka PJ, Farmer ER, Santos GW. Graft-versus-host disease in cyclosporin A-treated rats after syngeneic and autologous bone marrow reconstitution. J Exp Med 1983; 158: 1-8.
16. Hess AD, Horwitz L, Beschorner WE, Santos GW. Development of graft-vs-host disease-like syndrome in cyclosporinetreated rats after syngeneic bone marrow transplantation. I. Developmont of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity. J Exp Med 1985; 161: 718-730.
17. Jenkins MK, Schwartz RH, Pardoll DM. Effects of cyclosporine A on T cell development and clonal deletion. Science 1988; 241: 1655-1658.
18. Gao EK, Lo D, Cheney R, Kanagawa O, Sprent J. Abnormal Differentiation of thymocytes in mice treated with cyclosporin A. Nature 1988; 336: 176-179.
19. Miura Y, Ueda M, Takami A, Shiobara S, Nakao S, Hess AD. Enhancement of cyclosporin A-induced autologous graft-versus-host disease after peripheral blood stem cell transplantation by utilizing selected CD34(+) cells. Bone Marrow Transplant 2003; 32: 785-790.
20. Hess AD. Autologous graft-versus-host disease. J Hematother Stem Cell Res 2000; 9: 297.
21. Giralt S, Weber D, Colome M, Dimopoulos M, Mehra R, Van Besien K et al. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol 1997; 15: 667-673.
22. Kennedy MJ, Vogelsang GB, Beveridge RA, Farmer ER, Altomonte V, Huelskamp AM et al. Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1993; 11 478-484.
23. Park J, Lee MH, Lee HR, Park SH, Lee SH, Lee KE et al. Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia. Bone Marrow Transplant 2003; 32: 889-895.
24. Vogelsang G, Bitton R, Piantadosi S, Altomonte V, Horn T, Jones R et al. Immune modulation in autologous bone marrow transplantation: cyclosporine and gamma-interferon trial. Bone Marrow Transplant 1999; 24: 637-640.
25. Yeager AM, Vogelsang GB, Jones RJ, Farmer ER, Altomonte V, Hess AD et al. Induction of cutaneous graft-versus-host disease administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 1992; 79: 3031-3035.
26. Kennedy MJ, Vogelsang GB, Jones RJ, Farmer ER, Hess AD, Altomonte V et al. Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1994; 112: 249-257.
27. Rappeport J, Mihm M, Reinherz E, Lopansri S, Parkman R. Acute graft-versus-host disease in recipients of bone-marrow transplants from identical twin donors. Lancet 1979; 8145: 717-720.
28. Geller RB, Esa AH, Beschorner WE, Frondoza CG, Santos GW, Hess AD. Successful in vitro graft-versus-tumor effect against an Ia-bearing tumor using cyclosporine-induced syngeneic graft-versus-host disease in the rat. Blood 1989; 74: 1165-1171.
29. Bryson JS, Lake-Bullock H, Pflugh DL, Jennings CD, Stuart PM, Caywood BE et al. In vivo reactivity of T cell clones isolated from mice with syngeneic graft-versus-host disease. Transplantation 1995; 60 171-178.
30. Hess AD, Bright EC, Thoburn C, Vogelsang GB, Jones RJ, Kennedy MJ. Specificity of effector T lymphocytes in autologous graft-versus-host disease role of the major histocompatibility complex class II invariant chain peptide. Blood 1997; 89: 2203-2209.
31. Hess AD, Fischer AC, Horwitz L, Bright EC, Laulis MK. Characterization of peripheral autoregulatory mechanisms that prevent development of cyclosporin-induced syngeneic graft-versus-host disease. J Immunol 1994; 153: 400-411.
32. Ruvolo P, Bright E, Kennedy MJ, Morris L, Fischer A, Vogelsang G et al. Cyclosporine-induced autologous graft versus host disease: assessment of cytolytic effector mechanisms and the V beta T-cell receptor repertoire. Transplant Proc 1995; 27: 1363-1365.
33. Miura Y, Thoburn CJ, Bright EC, Sommer M, Lefell S, Ueda M. et al. Characterization of the T-cell repertoire in autologous graft-versus-host disease (GVHD): Evidence for the involvement of antigen-driven T-cell response in the development of autologous GVHD. Blood 2001; 98: 808-876.
34. Borrello I, Sotomayor EM, Rattis FM, Cooke SK, Gu L, Levitsky HI. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 2000; 95: 3011-3019.
35. de Arriba F, Corral J, Ayala F, Heras I, Moraleda JM, Osma MM et al Autoaggression syndrome resembling acute graft-versus-host disease grade IV after autologous peripheral blood stem cell transplantation for breast cancer. Bone Marrow Transplant 1999; 23: 621-624.
36. Carella AM, Gaozza E, Congiu A, Carlier P, Frassoni F, Valbonesi M et al. Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation in hematological malignancies. Ann Hematol 1991; 62: 156-159.
37. Yeager AM, Vogelsang GB, Jones RJ, Farmer ER, Hess AD, Santos GW. Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation for acute myeloid leukemia. Leuk Lymphoma 1993; 11: 215-220.
38. Gaspari AA, Cheng SF, DiPersio JF, Rowe JM. Roquinimex-induced graft-versus-host reaction after autologous bone marrow transplantation. J Am Acad Dermatol 1995; 33: 711-717.
39. Redman BG, Chou TH, Zalupski M, Uberti J, Flaherty L, Dan M et al. Phase I trial of sequential cyclophosphamide, cyclosporin A, and interferon-alpha in patients with cancer: Attempt to induce autologous graft-versus-host reaction to elicit an antitumor response. J Immunother Emphasis Tumor Immunol 1995; 18: 115-118.
40. Nakamura H, Nakao T, Ujiie H, Karasuno T, Teshima H, Komatsu K et al Induction of autologous graft-versus-host disease after autologous peripheral blood stem cell transplantation. J Allergy Clin Immunol 1909; 103: S457-S461.
41. van der Wall E, Horn T, Bright E, Passos-Coehlo JL, Bond S, Clarke B et al. Autologous graft-versus-host disease induction in advanced breast cancer: Role of peripheral blood progenitor cells. Br J Cancer 2000; 83: 1405-1411.
42. Miura Y, Ueda M, Zeng W, Wang H, Takani A, Yamazaki H et al. Induction of autologous graft-versus-host disease with cyclosporin A after peripheral blood stem cell transplantation: Analysis of factors affecting induction. J Allergy Clin Immunol 2000; 106: S51-S57.
43. Streetly M, Kazmi M, Radia D, Hoyle C, Schey SA. Second autologous transplant with cyclosporin/interferon alpha-induced graft versus host disease for patients who have failed first-line consolidation. Bone Marrow Transplant 2004, 33: 1131-1135.
44. Noga SJ, Horwitz L, Kim H, Laulis MK, Hess AD. Interferon-gamma potentiates the antitumor effect of cyclosporine-induced autoimmunity. J Hematother 1992; 1: 75-84.
45. Greiner J, Schmitt M, Li L, Giannopoulos K, Schmitt A, Dohner K et al Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood 2006; 108: 4109-4117.
46. Zenz T, Ritgen M, Dreger P, Krober A, Barth TF, Schlenk R et al. Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 2006; 108: 2127-2130.
47. Ohsuga Y, Rowe JM, Liesveld J, Burns RP, Gaspari AA. Dermatologic changes associated with roquinimex immunotherapy after autologous bone marrow transplant. J Am Acad Dermatol 2000; 43: 437-441.
48. Hess AD, Thoburn CJ. Immune tolerance to self-major histocompatibility complex class II antigens after bone marrow transplantation: Role of regulatory T cells. Biol Blood Marrow Transplant 2006; 12: 518-529.
49. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061.
50. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004; 200: 771-782.
51. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115 3623-3633.
52. Nemunaitis J. Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev Vaccines 2005; 4: 259-274.
53. Messina G, Quartarone E, Console G, Cuzzola M, Iacopino O, Martino M et al. Systemic aspergillosis in a patient with non-Hodgkin's lymphoma developing acute graft-versus-host disease after autologous peripheral blood stem cell transplantation. Haematologica 2002; 87: ECR22.